摘要
1999年由美国的Zhao和Drlica首先提出了防耐药突变浓度（MPC）和耐药突变选择窗（MSW）的假说。该假说认为每一种抗菌药物的浓度如果位于MSW内，那么细菌只需要一步突变而产生耐药，并且被选择性富集扩增，从而产生耐药。因此，这就为临床上抗菌药物的应用提供了一种新的给药策略，这种策略的关键在于将药物浓度提高到选择窗上界即MPC以上。近些年来，随着人们对该理论研究的深入，对该理论有了许多新的认识，为有效抑制细菌耐药及制定抗菌药物应用策略提供了新的思路和参考依据。
In 1999, Zhao and Drlica put forward the hypothesis of mutant prevention concentration （MPC） and mutant selection window（MSW）. They believe that for each antibacterial agents, if their concentration range exists in MSW,the drug-resistant mutants will arise and amplify which only need singlestep mutant. So,this hypothesis provides a newdosing strategy for clinic. The key of this strategy is that raise the antibiot concentration to the upper boundary of selection window：MPC. In recent years, along with the study in this hypothesis deeply, some new viewpoints have been arised about those hypothesis, which provides the new method to restrain the resistant problem.
出处
《国际呼吸杂志》
2009年第5期309-312,共4页
International Journal of Respiration
关键词
防耐药突变浓度
耐药突变选择窗
耐药
Mutant prevention concentration
Mutant selection window,Resistant
